Mydriacyl (Tropicamide)

Tropicamide works by selectively blocking muscarinic (M3) receptors in the iris sphincter and ciliary muscles. This antagonism prevents acetylcholine‑driven contraction, causing the pupil to dilate and the ciliary muscle to relax, which temporarily eliminates the eye’s ability to focus.

The specific dose and frequency are determined by the prescribing eye‑care professional. Typically, a single drop is instilled in the affected eye(s) and may be repeated after a short interval if greater dilation is required, but exact regimens should follow the prescriber’s instructions.

Safety data for tropicamide during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mydriacyl, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mydriacyl (tropicamide) provides rapid onset and relatively short duration of dilation compared with longer‑acting agents such as atropine. Phenylephrine, another alternative, works via adrenergic stimulation and may cause more cardiovascular effects. Tropicamide’s antimuscarinic action offers predictable cycloplegia with a favorable safety profile for routine diagnostic use.

Mydriacyl should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture. Keep the vial tightly sealed when not in use and discard any product that appears discolored or contaminated.

Mydriacyl is administered as an ocular drop. The prescriber typically instructs the patient to instill one drop into each eye, avoiding contact between the tip of the bottle and the ocular surface. The drop should be given at the recommended time before the examination, allowing sufficient time for dilation.

The most serious risks include acute angle‑closure glaucoma, which can cause a rapid increase in intra‑ocular pressure and requires emergency treatment, and severe allergic reactions such as anaphylaxis. Systemic anticholinergic effects like pronounced dry mouth, tachycardia, or confusion may also occur, especially in vulnerable patients.

Mydriacyl should be avoided in patients with known narrow‑angle or angle‑closure glaucoma, hypersensitivity to tropicamide or any component of the formulation, and in individuals taking concurrent ocular anticholinergic agents that could cause excessive dilation. The prescribing clinician must evaluate each patient’s suitability before use.